Omeros Revenue Growth Rates (OMER), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Omeros Corporation  (NASDAQ: OMER)
 

OMER's Revenue Growth by Quarter and Year

Omeros's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

OMER Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 39.98
1st Quarter March 83.04
FY 123.02





OMER Revenue second quarter 2026 Y/Y Growth Comment
Omeros Corporation reported Revenue surge of 386.92% year on year in the second quarter 2026, to $ 39.98 millions, this is lower than Omeros Corporation's recent average Revenue surge of 406.58%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 20 other companies have achieved higher Revenue growth. While Omeros Corporation' s Revenue doubling of 386.92% ranks overall at the positon no. 90 in the second quarter 2026.


OMER Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June 386.92 % - - -
1st Quarter March - - - -
FY   - - - -

Financial Statements
Omeros's second quarter 2026 Revenue $ 39.98 millions OMER's Income Statement
Omeros's second quarter 2025 Revenue $ 8.21 millions Quarterly OMER's Income Statement


OMER Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June -51.86 % - - -
1st Quarter March - - - -
FY (Year on Year)   - - - -


Back to OMER Growth rate Comparisons >> Back to OMER Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #21
Healthcare Sector #30
Overall #90

Revenue Y/Y Growth Statistics
High Average Low
6982.22 % 406.58 % -100 %
(Jun 30 2015)   (Mar 31 2018)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #21
Healthcare Sector #30
Overall #90
Revenue Y/Y Growth Statistics
High Average Low
6982.22 % 406.58 % -100 %
(Jun 30 2015)   (Mar 31 2018)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Omeros's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
721.39 % 40.07 % -88.46 %
(Jun 30 2015)  


OMER's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Omeros Corporation disclosed fall in Revenue from the first quarter by -51.86% to $ 39.98 millions, from $ 83.04 millions achived in the previous reporting period.

Within Major Pharmaceutical Preparations industry 187 other companies have achieved higher Revenue quarter on quarter growth. While Omeros's Revenue growth quarter on quarter, overall rank is 3688.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #188
Healthcare Sector #536
Overall #3688
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #188
Healthcare Sector #536
Overall #3688
Revenue Q/Q Growth Statistics
High Average Low
721.39 % 40.07 % -88.46 %
(Jun 30 2015)  


OMER's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Omeros Corporation disclosed fall in Revenue from the first quarter by -51.86% to $ 39.98 millions, from $ 83.04 millions achived in the previous reporting period.

Within Major Pharmaceutical Preparations industry 187 other companies have achieved higher Revenue quarter on quarter growth. While Omeros's Revenue growth quarter on quarter, overall rank is 3688.


Omeros's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - - - - -
Seq. Revenue Growth (TTM) Overall Ranking # # # # #


Cumulative Revenue growth Comment
In the Jun 30 2026 period, Omeros's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Omeros Corporation achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
In the Jun 30 2026 period, Omeros's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Omeros Corporation achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
OMER's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Nuvation Bio Inc 644.35%$ 644.350 millions
Tonix Pharmaceuticals Holding Corp 577.88%$ 577.878 millions
Allogene Therapeutics Inc 567.50%$ 567.500 millions
Brightspring Health Services Inc 555.52%$ 555.518 millions
Bullfrog Ai Holdings Inc 547.64%$ 547.638 millions
Northwest Biotherapeutics Inc516.03%$ 516.031 millions
Vistagen Therapeutics Inc 504.92%$ 504.918 millions
Kymera Therapeutics Inc 466.40%$ 466.399 millions
Surrozen Inc 408.65%$ 408.647 millions
Regenxbio Inc 405.73%$ 405.731 millions
Insmed Inc393.78%$ 393.775 millions
Omeros Corporation387.10%$ 387.096 millions
Catheter Precision Inc 380.66%$ 380.660 millions
Macrogenics Inc 377.97%$ 377.974 millions
Vireo Growth Inc.335.47%$ 335.470 millions
Dianthus Therapeutics Inc 294.30%$ 294.301 millions
Miragen Therapeutics Inc 278.67%$ 278.667 millions
Alpha Cognition Inc.267.56%$ 267.556 millions
Agios Pharmaceuticals Inc 259.25%$ 259.253 millions
Omniab Inc 244.24%$ 244.239 millions
Medicinova Inc 240.60%$ 240.596 millions
Clene Inc 233.33%$ 233.333 millions
Editas Medicine Inc 232.31%$ 232.309 millions
Urogen Pharma Ltd 206.17%$ 206.174 millions
Sintx Technologies Inc 199.34%$ 199.338 millions


About Omeros Revenue Growth Rates (OMER), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Omeros Corp (CIK 1285819).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001437749-26-027318
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Omeros Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.